Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy

Luciana Schultz, Roula Albadine, Jessica Hicks, Sana Jadallah, Angelo Michael Demarzo, Ying Bei Chen, Matthew E. Neilsen, Mark L. Gonzalgo, David Sidransky, Mark Schoenberg, George J. Netto

Research output: Contribution to journalArticle

Abstract

Background: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. Methods: Tissue microarrays were constructed from 132 cystectomies (1994-2002). Immunohistochemistry was performed for Pten, c-myc, p27, phosphorylated (phos)Akt, phosS6, and 4E-BP1. Markers were evaluated for pattern, percentage, and intensity of staining. Results: Mean length of follow-up was 62.6 months (range, 1-182 months). Disease progression, overall survival (OS), and disease-specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E-BP1. Pten, p27, phosAkt, phosS6, and 4E-BP1 expression correlated with pathologic stage (pathological stage; P

Original languageEnglish (US)
Pages (from-to)5517-5526
Number of pages10
JournalCancer
Volume116
Issue number23
DOIs
StatePublished - Dec 1 2010

Fingerprint

Cystectomy
Sirolimus
Urinary Bladder
Carcinoma
Urothelium
Cell Shape
Cell Movement
Disease Progression
Survival Rate
Immunohistochemistry
Cell Proliferation
Staining and Labeling
Morbidity
Mortality
Therapeutics

Keywords

  • 4E-BP1
  • Akt
  • bladder
  • c-myc
  • mammalian target of rapamycin
  • p27
  • phosS6
  • Pten
  • urothelial carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. / Schultz, Luciana; Albadine, Roula; Hicks, Jessica; Jadallah, Sana; Demarzo, Angelo Michael; Chen, Ying Bei; Neilsen, Matthew E.; Gonzalgo, Mark L.; Sidransky, David; Schoenberg, Mark; Netto, George J.

In: Cancer, Vol. 116, No. 23, 01.12.2010, p. 5517-5526.

Research output: Contribution to journalArticle

Schultz, L, Albadine, R, Hicks, J, Jadallah, S, Demarzo, AM, Chen, YB, Neilsen, ME, Gonzalgo, ML, Sidransky, D, Schoenberg, M & Netto, GJ 2010, 'Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy', Cancer, vol. 116, no. 23, pp. 5517-5526. https://doi.org/10.1002/cncr.25502
Schultz, Luciana ; Albadine, Roula ; Hicks, Jessica ; Jadallah, Sana ; Demarzo, Angelo Michael ; Chen, Ying Bei ; Neilsen, Matthew E. ; Gonzalgo, Mark L. ; Sidransky, David ; Schoenberg, Mark ; Netto, George J. / Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. In: Cancer. 2010 ; Vol. 116, No. 23. pp. 5517-5526.
@article{7192126d3e4e4ea48cd2386933d28a04,
title = "Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy",
abstract = "Background: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. Methods: Tissue microarrays were constructed from 132 cystectomies (1994-2002). Immunohistochemistry was performed for Pten, c-myc, p27, phosphorylated (phos)Akt, phosS6, and 4E-BP1. Markers were evaluated for pattern, percentage, and intensity of staining. Results: Mean length of follow-up was 62.6 months (range, 1-182 months). Disease progression, overall survival (OS), and disease-specific survival (DSS) rates were 42{\%}, 60{\%}, and 68{\%}, respectively. Pten showed loss of expression in 35{\%} of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E-BP1. Pten, p27, phosAkt, phosS6, and 4E-BP1 expression correlated with pathologic stage (pathological stage; P",
keywords = "4E-BP1, Akt, bladder, c-myc, mammalian target of rapamycin, p27, phosS6, Pten, urothelial carcinoma",
author = "Luciana Schultz and Roula Albadine and Jessica Hicks and Sana Jadallah and Demarzo, {Angelo Michael} and Chen, {Ying Bei} and Neilsen, {Matthew E.} and Gonzalgo, {Mark L.} and David Sidransky and Mark Schoenberg and Netto, {George J.}",
year = "2010",
month = "12",
day = "1",
doi = "10.1002/cncr.25502",
language = "English (US)",
volume = "116",
pages = "5517--5526",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "23",

}

TY - JOUR

T1 - Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy

AU - Schultz, Luciana

AU - Albadine, Roula

AU - Hicks, Jessica

AU - Jadallah, Sana

AU - Demarzo, Angelo Michael

AU - Chen, Ying Bei

AU - Neilsen, Matthew E.

AU - Gonzalgo, Mark L.

AU - Sidransky, David

AU - Schoenberg, Mark

AU - Netto, George J.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Background: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. Methods: Tissue microarrays were constructed from 132 cystectomies (1994-2002). Immunohistochemistry was performed for Pten, c-myc, p27, phosphorylated (phos)Akt, phosS6, and 4E-BP1. Markers were evaluated for pattern, percentage, and intensity of staining. Results: Mean length of follow-up was 62.6 months (range, 1-182 months). Disease progression, overall survival (OS), and disease-specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E-BP1. Pten, p27, phosAkt, phosS6, and 4E-BP1 expression correlated with pathologic stage (pathological stage; P

AB - Background: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. Methods: Tissue microarrays were constructed from 132 cystectomies (1994-2002). Immunohistochemistry was performed for Pten, c-myc, p27, phosphorylated (phos)Akt, phosS6, and 4E-BP1. Markers were evaluated for pattern, percentage, and intensity of staining. Results: Mean length of follow-up was 62.6 months (range, 1-182 months). Disease progression, overall survival (OS), and disease-specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E-BP1. Pten, p27, phosAkt, phosS6, and 4E-BP1 expression correlated with pathologic stage (pathological stage; P

KW - 4E-BP1

KW - Akt

KW - bladder

KW - c-myc

KW - mammalian target of rapamycin

KW - p27

KW - phosS6

KW - Pten

KW - urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=78649556380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649556380&partnerID=8YFLogxK

U2 - 10.1002/cncr.25502

DO - 10.1002/cncr.25502

M3 - Article

VL - 116

SP - 5517

EP - 5526

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 23

ER -